Outpace Bio Analysis: $200M Raised
What is Outpace Bio?
Outpace Bio focuses on revolutionizing solid tumor treatment through AI-powered protein engineering. Their proprietary technologies, including OUTSMART™, OUTLAST™, and OUTSPACER™, aim to enhance the safety and efficacy of CAR-T therapies. The company addresses multiple challenges in cancer treatment by programming cells to make better decisions within the tumor microenvironment.
Location
700 Dexter Avenue North, Suite 300, Seattle, Washington 98109, United States
Employees
51-200
Founded
2020
Product Features & Capabilities
- OUTSMART™ designed cytokines
- OUTLAST™ T cell persistence technology
- OUTSPACER™ optimized CAR
- OUTSAFE™ safety switch
- CO-LOCKR™ logic gated targeting
Use Cases
Stimulate immune responses in solid tumors; Enhance CAR T cell function for better cancer cell killing; Improve T cell persistence in patients; Provide safety features for powerful cell therapies; Enable targeted treatment of diverse cancer types
How much Outpace Bio raised
Funding - $200M
HQ Full Address
700 Dexter Avenue North, Suite 300, Seattle, Washington 98109, United States
Other Considerations
Raised significant funding; Collaborates with leading biopharma and academic institutions; Extensive experience in protein design with over 100,000 hours logged; Tested over 10,000 constructs in research
See something that needs updating? Suggest edits to this profile.